Body Mass Index Category and Adverse Events in Hospitalized Children

Elizabeth Eby Halvorson1, Danielle P Thurtle2, Ashley Easter1

  • 1Department of Pediatrics, Wake Forest School of Medicine (EE Halvorson and A Easter), Winston-Salem, NC.

Academic Pediatrics
|September 20, 2021
PubMed

Insights

This study found no link between a child's body mass index (BMI) category and the rate or severity of adverse events (AEs). However, initial findings suggested a higher rate of preventable AEs in children with obesity.

Area of Science:

  • Pediatric patient safety
  • Clinical outcomes research
  • Body Mass Index (BMI) and health

Background:

  • Adverse events (AEs) in pediatric populations can impact patient outcomes.
  • Understanding the relationship between body mass index (BMI) categories and AEs is crucial for targeted interventions.
  • Previous research has not definitively established a link between BMI and AE rates, severity, or preventability in children.

Purpose of the Study:

  • To investigate the association between patient body mass index (BMI) category and adverse event (AE) rate, severity, and preventability.
  • To analyze AE data in a cohort of children discharged from an academic children's hospital.
  • To identify potential risk factors related to BMI in pediatric patient safety.

Main Methods:

  • Retrospective cohort study of 680 pediatric patients (ages 2-17) discharged between June and October 2018.
  • Patients categorized into underweight, normal weight, overweight, and obesity based on BMI.
  • Adverse events identified using the Global Assessment of Pediatrics Patient Safety trigger tool and scored for harm and preventability.

Main Results:

  • A total of 270 AEs were recorded across 834 encounters.
  • No significant association was found between BMI category and the overall rate of AEs (P = .46).
  • No associations were observed between BMI category and AE severity; initial analysis suggested increased preventable AEs in obesity, but this did not persist in multivariable modeling.

Conclusions:

  • This single-center study did not establish a clear association between BMI category and the rate, severity, or preventability of AEs in pediatric patients.
  • Further research with larger, diverse cohorts may be needed to explore subtle relationships.
  • Current findings suggest that BMI category alone may not be a primary predictor of AEs in this pediatric population.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
721
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
24
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
38
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
31
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
24
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
47